Heather J. Dalton

3.2k total citations
29 papers, 990 citations indexed

About

Heather J. Dalton is a scholar working on Molecular Biology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, Heather J. Dalton has authored 29 papers receiving a total of 990 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Cancer Research and 10 papers in Reproductive Medicine. Recurrent topics in Heather J. Dalton's work include Ovarian cancer diagnosis and treatment (10 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Heather J. Dalton is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Angiogenesis and VEGF in Cancer (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Heather J. Dalton collaborates with scholars based in United States, China and Puerto Rico. Heather J. Dalton's co-authors include Anil K. Sood, Gabriel Lopez‐Berestein, Behrouz Zand, Cristina Ivan, Sunila Pradeep, Rajesha Rupaimoole, Wei Hu, Rebecca A. Previs, Nicholas B. Jennings and Vianey González-Villasana and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Heather J. Dalton

28 papers receiving 979 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Heather J. Dalton 424 332 251 170 158 29 990
Behrouz Zand 364 0.9× 350 1.1× 204 0.8× 143 0.8× 86 0.5× 34 869
Justin Bottsford-Miller 559 1.3× 591 1.8× 258 1.0× 324 1.9× 165 1.0× 42 1.4k
Toshihide Matsumoto 476 1.1× 272 0.8× 145 0.6× 168 1.0× 119 0.8× 58 973
Mélanie Mestdagt 568 1.3× 382 1.2× 159 0.6× 211 1.2× 118 0.7× 13 1.0k
David A. Leinster 383 0.9× 486 1.5× 485 1.9× 246 1.4× 175 1.1× 7 1.1k
Masahiro Sato 739 1.7× 231 0.7× 166 0.7× 219 1.3× 45 0.3× 26 1.0k
Heather S. Bevan 796 1.9× 226 0.7× 78 0.3× 227 1.3× 62 0.4× 12 1.1k
Julia M. Jansen 368 0.9× 296 0.9× 415 1.7× 173 1.0× 126 0.8× 21 902
Alexander Gheldof 660 1.6× 437 1.3× 77 0.3× 285 1.7× 74 0.5× 26 1.1k
Antigone Sourla 504 1.2× 432 1.3× 85 0.3× 259 1.5× 99 0.6× 52 1.4k

Countries citing papers authored by Heather J. Dalton

Since Specialization
Citations

This map shows the geographic impact of Heather J. Dalton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather J. Dalton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather J. Dalton more than expected).

Fields of papers citing papers by Heather J. Dalton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather J. Dalton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather J. Dalton. The network helps show where Heather J. Dalton may publish in the future.

Co-authorship network of co-authors of Heather J. Dalton

This figure shows the co-authorship network connecting the top 25 collaborators of Heather J. Dalton. A scholar is included among the top collaborators of Heather J. Dalton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather J. Dalton. Heather J. Dalton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dalton, Heather J., Nicole D. Fleming, Charlotte C. Sun, et al.. (2017). Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecologic Oncology. 145(1). 37–40. 42 indexed citations
2.
Huang, Jie, Wei Hu, Limin Hu, et al.. (2016). Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics. 15(6). 1344–1352. 41 indexed citations
3.
González-Villasana, Vianey, Enrique Fuentes‐Mattei, Cristina Ivan, et al.. (2015). Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clinical Cancer Research. 21(9). 2127–2137. 63 indexed citations
4.
Thanapprapasr, Duangmani, Rebecca A. Previs, Wei Hu, et al.. (2015). PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics. 14(6). 1466–1475. 15 indexed citations
5.
Previs, Rebecca A., Guillermo N. Armaiz-Peña, Yvonne G. Lin, et al.. (2015). Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Molecular Cancer Therapeutics. 14(12). 2677–2686. 11 indexed citations
6.
Hansen, Jean M., Keith Baggerly, Yinghong Wang, et al.. (2015). Homologous recombination deficiency in endometrioid uterine cancer: An unrecognized phenomenon. Gynecologic Oncology. 137. 21–21. 2 indexed citations
7.
Wen, Yunfei, Whitney A. Spannuth Graybill, Rebecca A. Previs, et al.. (2014). Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. Clinical Cancer Research. 21(2). 448–459. 53 indexed citations
8.
Bottsford-Miller, Justin, Hyun Jin Choi, Heather J. Dalton, et al.. (2014). Differential Platelet Levels Affect Response to Taxane-Based Therapy in Ovarian Cancer. Clinical Cancer Research. 21(3). 602–610. 73 indexed citations
9.
Roh, Ju‐Won, Jie Huang, Wei Hu, et al.. (2014). Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clinical Cancer Research. 20(10). 2740–2750. 15 indexed citations
10.
Tucker, Susan L., Kshipra M. Gharpure, Shelley M. Herbrich, et al.. (2014). Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research. 20(12). 3280–3288. 68 indexed citations
11.
Dalton, Heather J., Sunila Pradeep, Vianey González-Villasana, et al.. (2014). Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology & Therapy. 15(8). 1061–1067. 33 indexed citations
12.
Cho, Min Soon, Hernan G. Vasquez, Rajesha Rupaimoole, et al.. (2014). Autocrine Effects of Tumor-Derived Complement. Cell Reports. 6(6). 1085–1095. 165 indexed citations
13.
Dalton, Heather J., et al.. (2014). Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways. PubMed. 1(1). 4–4. 2 indexed citations
14.
Dalton, Heather J., James V. Fiorica, Candace K. McClure, et al.. (2014). In vitro chemoresponse in metachronous pairs of gyneclologic cancers. PubMed. 1(1). 7–7. 1 indexed citations
15.
Stone, Rebecca L., Keith Baggerly, Guillermo N. Armaiz-Peña, et al.. (2014). Focal adhesion kinase. Cancer Biology & Therapy. 15(7). 919–929. 41 indexed citations
16.
Choi, Hyun Jin, Seung Wook Kim, Sunila Pradeep, et al.. (2014). Abstract 2: Paxillin enhances angiogenesis through transcriptional regulation of Src in ovarian cancer. Cancer Research. 74(19_Supplement). 2–2. 1 indexed citations
17.
Kang, Yu, Wei Hu, Cristina Ivan, et al.. (2013). Role of Focal Adhesion Kinase in Regulating YB–1–Mediated Paclitaxel Resistance in Ovarian Cancer. JNCI Journal of the National Cancer Institute. 105(19). 1485–1495. 156 indexed citations
18.
Miyake, Takahito, Sunila Pradeep, Behrouz Zand, et al.. (2013). Abstract 5541: Therapeutic targeting of CRM1 in ovarian cancer.. Cancer Research. 73(8_Supplement). 5541–5541. 5 indexed citations
19.
Ivan, Cristina, Wei Hu, Justin Bottsford-Miller, et al.. (2012). Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecologic Oncology. 128(3). 506–511. 32 indexed citations
20.
Dalton, Heather J., Xinhua Yu, Daniel S. Kapp, et al.. (2011). An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecologic Oncology. 124(2). 199–204. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Behrouz Zand Breakdown of academic impact, for papers by Justin Bottsford-Miller Breakdown of academic impact, for papers by Toshihide Matsumoto Breakdown of academic impact, for papers by Mélanie Mestdagt Breakdown of academic impact, for papers by David A. Leinster Breakdown of academic impact, for papers by Masahiro Sato Breakdown of academic impact, for papers by Heather S. Bevan Breakdown of academic impact, for papers by Julia M. Jansen Breakdown of academic impact, for papers by Alexander Gheldof Breakdown of academic impact, for papers by Antigone Sourla
Rankless by CCL
2026